Evidence map›Paper›PMID 34456727›Full record

ArticleFrontiers in pharmacology2021

SMG9 Serves as an Oncogene to Promote the Tumor Progression

Xing Jin, Jie Yin, Hongling Zhu, Weikang Li, Kewei Yu, Miao Liu, Xiujuan Zhang, Miaolian Lu, Zemin Wan, Xianzhang Huang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Nonsense-mediated mRNA decay: friend or foe in cancer biology?Cell communication and signaling : CCS · 2026
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xing JinSecond Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jie YinDepartment of Nuclear Medicine, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
Hongling ZhuDepartment of Gynecology, Shanghai Armed Police Corps Hospital, Shanghai, China.
Weikang LiSecond Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Kewei YuSecond Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Miao LiuDepartment of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiujuan ZhangDepartment of Liver Disease, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Miaolian LuDepartment of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Zemin WanSecond Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xianzhang HuangSecond Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangzhou University of Chinese Medicine · CNYangzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

EMThepatocellular carcinomaprognostic biomarkerSMG9therapeutic target

Identifiers

PMID34456727
PMCPMC8397484
OpenAlexW3192026587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.